The BCL3 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the BCL3 gene in a heterogeneous pool of A-549 cells. This product provides a powerful loss-of-function model for investigating BCL3-dependent signaling without the need for clonal isolation, enabling studies that reflect population-level variations in knockout efficiency and compensatory mechanisms. By targeting BCL3, a critical transcriptional regulator, these cells allow researchers to dissect its role in NF-??B-driven transcription and associated cellular processes.
The host cell line, A-549, is a well-characterized human lung adenocarcinoma epithelial cell line derived from a 58-year-old male. These adherent epithelial-like cells are a widely accepted model for studying lung adenocarcinoma biology, alveolar epithelial function, and cancer signaling pathways. A-549 cells exhibit robust activation of inflammatory and proliferative signaling cascades, making them an ideal system for evaluating the impact of BCL3 knockout on tumor cell behavior.
BCL3 functions primarily as a transcriptional coactivator or corepressor by associating with NF-??B p50 or p52 homodimers on DNA, thereby modulating the expression of a broad array of target genes. Its activity is induced by diverse stimuli, including TNF-??, IL-1??, and lipopolysaccharide (LPS), which trigger signaling through upstream kinases. BCL3 interacts with multiple partners such as STAT3, HDAC1, HDAC3, and CSN5/Jab1, and it orchestrates the transcription of downstream effectors like CCND1 (cyclin D1), MYC (c-Myc), BCL2, IL-6, survivin (BIRC5), and MMP9. Through these interactions, BCL3 influences pathways including NF-??B, STAT3, and Toll-like receptor signaling.
In A-549 cells, BCL3-mediated regulation of NF-??B target genes is essential for maintaining proliferation, survival, and inflammatory responses characteristic of lung adenocarcinoma. Disruption of BCL3 using this polyclonal knockout population impairs the induction of key growth and anti-apoptotic genes, providing a physiologically relevant model to study the molecular underpinnings of tumorigenesis. The heterogeneous knockout pool enables the observation of dose-dependent effects and cellular heterogeneity, closely mimicking the complexity of tumor cell populations.
This product is ideally suited for a wide range of experimental applications, including NF-??B signaling studies, gene expression profiling by RNA-seq or RT-qPCR, chromatin immunoprecipitation (ChIP-qPCR) to assess p50/p52 DNA binding, western blotting for BCL3 and downstream targets, flow cytometry-based apoptosis and cell cycle analysis, Transwell migration and invasion assays, and high-throughput drug sensitivity screens. NF-??B luciferase reporter assays can also be employed to quantify pathway activity. For further technical information or inquiries, please contact Ascent Research.
